Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ilaris in moderate to severe chronic idiopathic urticaria
NCT01635127Phase 2Unknown
- Sponsor
- University of Zurich
- Start
- Jun 2012
- Primary completion
- Dec 2016
- Countries
- 1
01
Overview
A Phase 2 trial of canakinumab in chronic idiopathic urticaria (CIU), sponsored by University of Zurich. Status: unknown.
02
Drugs
canakinumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NCT01635127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01635127.